Biocracked
**Approach:** Lab in action. **Palette:** Bold color field, mustard yellow.

A close, slightly high three-quarter view of a hand in a magenta-purple nitrile glove holding a clear 12-well cell culture plate. Each well is filled with salmon-pink culture medium. A multichannel pipette hovers over one well, with a single droplet caught just before it falls. The background is a seamless, saturated mustard-yellow surface and wall, with a soft shadow under the plate. Bright, even studio light comes from the upper left, giving crisp highlights on the plastic rims and a soft glow through the liquid. The depth of field is shallow, so the far wells blur gently. A tiny electric-green cap on a tube sits in the corner of the frame. The mood is calm, precise and curious, with a clean, graphic, editorial feel. No text or labels.
Peptides

Semaglutide Ba Ya Rage Kwayoyin Tsoka na Dan Adam. To Me Ya Sa Akwai Rashin Tsoka?

Dr. Synapse · · 6 min read

Semaglutide Ba Ya Rage Kwayoyin Tsoka na Dan Adam. To Me Ya Sa Akwai Rashin Tsoka?

Bayanan labarin: Shin semaglutide yana cin tsokar ka? Sabon binciken GeroScience ya yi amfani da maganin kai tsaye a kan ƙwayoyin tsoka na manya masu kiba, kuma ƙwayoyin ba su nuna alamar lalacewa ba. Babu wata alamar atrophy, babu canjin secretome, har ma GIP ya ƙara kauri ga myotubes bayan kwana takwas. Semaglutide ya rage ɗan ƙanƙanta samar da ATP ta glycolysis, kuma GLP‑1 receptors ba su yawaita a ƙwayoyin ba. Sakamakon na nuna cewa asarar tsoka da ake gani a asibiti na da alaƙa da ƙarancin kalori da rage ɗagawa, ba da kai tsaye ga maganin ba.


Matsalolin rage kiba da semaglutide da sauran magungunan GLP‑1 suna da wani ƙarin damuwa: suna iya cin tsoka. Sabon bincike a cikin GeroScience ya nuna cewa a matakin ƙwayar tsoka kai tsaye, wannan zargi na iya zama kuskure. Lokacin da masu bincike suka ba myotubes na mutane semaglutide ko GIP, ƙwayoyin ba su nuna alamar lalacewa ba. Ba su kunna atrophy ba, ba su saki sinadaran ƙumburi ba, kuma ba su rasa kauri ba.

Sakamakon ba ya kawar da batun asarar ƙashin jiki gaba ɗaya, sai dai yana mayar da hankali kan wani ɓangare na canjin nauyi.

Tambayar Da Ke Bayan Binciken

A gwaje‑gwajen asibiti, magungunan GLP‑1 receptor agonists da dual GIP/GLP‑1 agonists suna haifar da raguwar nauyi mai sauri. Haka kuma, suna rage yawan ƙashi da tsoka, abin da ke ƙara damuwa ga manya da ke fama da sarcopenia. Don haka, fahimtar ko maganin yana tasiri kai tsaye kan tsoka ko kuwa sakamakon yanayin cin abinci da motsa jiki yana da matuƙar muhimmanci.

Akwai hujjoji guda biyu. Na farko shine tasirin kai tsaye na magani – ko yana aiki a kan ƙwayoyin tsoka har ya jawo lalacewa. Na biyu shine tasirin gaba ɗaya – mutane na cin ƙarancin kalori, galibi ƙarancin furotin, kuma suna yin ƙaramin motsa jiki, don haka tsoka na raguwa kamar yadda yake faruwa a duk wani yanayi na rashin kuzari. Ditchfield, Macleod da Price sun tsara gwaje‑gwaje don tantance waɗannan abubuwan a yanayi mai tsabta.

Yadda Gwajin Ya Gudana

Ƙungiyar ta samo primary myoblasts, wato ƙwayoyin farko na tsoka, daga ƙashin tsoka na manya masu kiba da aka ɗauka a tiyata ta ortopedi. An zaɓi wannan rukunin domin su ne za su fi samun damar karɓar maganin incretin kuma su fi fuskantar asarar tsoka.

Masu binciken sun fara tantance ko waɗannan ƙwayoyin na da masu karɓar da suka dace. Sannan suka canza su zuwa myotubes kuma suka ba su semaglutide ko peptide na GIP. An auna abubuwa masu zuwa:

  • Bayyanar kwayoyin atrophy ta hanyar qPCR
  • Canjin secretome ta amfani da Olink Reveal proteomic panel
  • Metabolism na mitochondria da glycolytic ta amfani da Seahorse XF ATP rate assay, tare da auna shan glucose da fitar da lactate
  • Kaurin myotube da bambance‑bambancen sa ta hanyar immunofluorescence

Masu Karɓa: GIPR Na Nan, GLP‑1R Ba Su Yawaita

An gano mRNA na GIPR a dukkan masu ba da gudummawa. Amma mRNA na GLP‑1R ba a gan shi ba ta hanyar PCR. Ta amfani da LUXendin645 flow cytometry a cikin samfuran uku, ƙungiyar ta gano ƙananan matakan furotin na GLP‑1R a saman ƙwayoyin – kusan kashi 51‑66 cikin dari na myoblasts ne ke ɗauke da su.

Wannan sakamako na tunatar da mu cewa gano masu karɓa ya danganta da hanyar da aka yi amfani da ita. Rashin ganewar mRNA ba yana nufin babu furotin ba, kuma ƙananan matakan masu karɓa a saman ƙwaya na iya haifar da tasiri ƙanana, ko da ba su haifar da manyan canje‑canje a cikin ƙwayar ba. Bayanai daga wasu masu bincike sun nuna cewa ƙwayoyin tsoka na ɗan adam, a mafi yawan lokuta, suna da ƙarancin kayan aiki don amsawa ga GLP‑1 kai tsaye.

Babu Alamun Atrophy, Babu Canjin Secretome

Babban sakamakon binciken shine rashin wani abu da ya faru. Ko semaglutide ko GIP ba su canza bayyanar kwayoyin atrophy ba. Binciken secretome – wato nazarin furotin da ƙwayoyin ke saki – bai gano wani bambanci mai ƙima ba. Idan magungunan suna guba ga tsoka ko suna haifar da siginar damuwa, a nan ne za a ga su.

Kaurin myotube da bambance‑bambancen su suma an kiyaye. Babu magani da ya hana ƙwayoyin haɗuwa da ƙirƙirar myotubes, don haka myogenesis ta ci gaba lafiya.

Ɗan Canjin Metabolik

An ga tasiri guda ɗaya kawai: semaglutide ya rage saurin samar da ATP na glycolytic da na gaba ɗaya, tare da rage fitar da lactate, alamar ƙananan raguwar glycolysis. Abubuwan mitochondria ba su canza ba.

Wannan canjin na laushi ne, ba alamar lahani ga ƙwaya ba, kuma binciken bai nuna cewa yana cutar da aikin tsoka. Duk da haka, ya kamata a ci gaba da bibiyar sa, domin ƙananan raguwar glycolysis na iya tasiri a cikin tsoka mai rai, inda iskar ƙarfi, hormones da jijiyoyi ke hulɗa da juna.

GIP Ma Zai Iya Taimakawa

A wani yanayi na ban mamaki, GIP ya ƙara kaurin myotube bayan kwanaki takwas na magani. Wannan abu ne da aka lura a cikin in‑vitro kuma ba yana nufin GIP zai gina tsoka a jikin mutum ba, amma yana ƙalubalantar tunanin cewa siginar incretin na da tasiri catabolic ga ƙwayoyin tsoka. Haka kuma, yana ƙara wa dual agonists kamar tirzepatide ƙarfi, domin sukan yi aiki a kan hanyoyin GIP da GLP‑1.

Menene Wannan Ke Nufi Ga Manya

Masu bincike sun kammala da cewa ƙara masu karɓar GLP‑1 da GIP kai tsaye ba ya haifar da manyan tasirin atrophic, inflammatory, morphological, myogenic ko mitochondrial a cikin waɗannan ƙwayoyin. Wannan ya dace da bayanan asibiti da ke nuna asarar ƙashi da tsoka a wasu marasa lafiya.

Idan muka ɗauki wannan fassarar a matsayin gaskiya, hankalin maganin zai mayar da hankali daga “maganin guba ga tsoka” zuwa yanayin da ke haifar da asara:

  • Rashin kuzari: raguwar nauyi mai sauri galibi tana cinye ƙashi da tsoka ba tare da la’akari da yadda aka cimma shi ba.
  • Karancin furotin: rashin isasshen furotin a abinci na iya ƙara wa manya matsalar asarar tsoka.
  • Ɗagawa: rashin motsa jiki da ƙasa da nauyi na rage ƙarfafa tsoka. Horon ƙarfi shi ne maganin da ya fi dacewa.

Wadannan ba sabbin ra'ayoyi ba ne, amma wannan bincike ya ƙara hujja daga matakin ƙwaya don tallafa wa shawarar. Yana nuna cewa kariya ga tsoka yayin amfani da magungunan incretin za ta dogara ne kan ingantaccen abinci da motsa jiki, ba kan gujewa magani ba.

Muhimman Kiyaye

Wannan bincike an yi shi a cikin in‑vitro. Myotubes da aka haifa a cikin tukunya ba su da jini, jijiyoyi, hormones masu yawo, ƙwayoyin garkuwar jiki, ko sauran abubuwan da ke tasiri a jikin mutum. Magunguna na iya shafar tsoka ta hanyoyi daban‑daban – kamar tasirin a kan kitse, hanta, hanji ko kumburi – waɗanda wannan samfurin ba ya ɗauka. Binciken furotin na GLP‑1R an iyakance ga masu ba da gudummawa uku, kuma su ne manya masu kiba da aka ɗauka a tiyata ta ortopedi, ba za su wakilci dukkan marasa lafiya ba. Haka kuma, yanayin in‑vitro na iya ba da sakamako da ba su dace da yanayin a jiki ba.

Sakamakon ya nuna cewa ba a ga wata alamar lalata tsoka ta hanyar masu karɓa a wannan samfurin ba. Wannan ba yana nufin cewa magungunan ba su da tasiri ga tsoka a mutane ba; har yanzu akwai buƙatar ƙarin gwaje‑gwaje a asibiti.

Gabaɗaya

Ga duk wanda ke damuwa da cewa semaglutide na “ƙone tsoka a hankali”, wannan bincike yana ba da ɗan sassauci: myotubes na ɗan adam da aka ba da semaglutide ko GIP ba su nuna alamun atrophy ko canjin ƙira ba. Babban haɗari na iya kasancewa a wajen yadda maganin ke amfani da shi – wato cin abinci ƙasa da ƙima, ƙarancin furotin, da ƙasa da motsa jiki. Gwaje‑gwajen asibiti da ke haɗa maganin incretin da ingantaccen shan furotin da horon ƙarfi a manya za su kasance gwajin gaskiya na wannan tunani.

Original study

Read the original research on pubmed.ncbi.nlm.nih.gov →

This article summarizes published research for general information. It is not medical advice.

DS

Written by

Dr. Synapse

Dr. Synapse writes for Biocracked: biohacking science, longevity & human performance.

Related Articles

Approach: Macro science, the human outcome angle through tissue. Palette: D, bold color field.

Extreme close-up of a cross-section of raw beef thigh muscle, used as a stand-in for human thigh tissue. It is shot straight on and slightly from above, on a saturated tomato-red seamless backdrop. Fine white fat marbling threads run through the dark red muscle fibers. On one half the marbling is dense and lacy, and on the other it is sparse and clean, so the contrast reads as a before and after. A thin, translucent calipers-style steel ruler lies along the edge, with no markings readable. Lighting is soft, directional studio light from the upper left, with crisp highlights on the glistening fibers and gentle warm shadows. A single small electric green surgical marker dot sits on the tissue. The mood is analytical, tense and uncertain, with shallow depth of field and sharp detail on the fat texture.
longevity

Semaglutide Mai Girma da Tsokar Cinyoyi: Abinda MRI Ya Nuna

BY HELIX WARD ·

Binciken MRI da aka yi a cikin gwajin STEP UP ya duba abin da ke faruwa bayan makonni 72 na amfani da semaglutide mai ƙarfi (7.2 mg) akan tsarin jiki, ciki har da tsokar cinyoyi. An sami raguwar kitse sosai, kusan lita 11 idan aka kwatanta da placebo, kuma kitse a cikin tsokar cinyoyi ya ragu sosai. Girman tsokar cinyoyi ya ragu da kusan lita 1.1, canjin da bai kai matsayin ƙididdiga ba (p = 0.07) amma tazara na dogara tana nuni da asara. Tunda an duba mutum 55 kawai, tare da placebo guda shida, kuma kamfanin Novo Nordisk ya shiga cikin binciken, sakamakon na nuni ne kawai ba tabbatacce ba.

Approach 3, the human outcome, in palette B, warm.

Low three-quarter rear angle, shot with a 50mm lens at shallow depth of field. A middle-aged person's forearm and hand grip a loaded barbell mid-deadlift, the tendons and the muscle of the forearm clearly defined, with chalk dust hanging in the air. Their face is out of frame. The setting is a plain home garage gym with a rubber floor and a rack softly blurred in the background. Low golden-hour sunlight comes through an open roll-up door and rakes across the skin and the knurled steel, casting long warm shadows. Amber, copper and honey tones dominate, with matte black plates for contrast. A tiny electric green silicone wristband or a small green pen injector resting on a nearby shelf adds a subtle accent. The mood is determined, quiet and hopeful.
metabolism

Game da Tirzepatide? Ɗaga Nauyi Ya Ceton 1.1 kg na Tsokoki

BY REX MERIDIAN ·

Tirzepatide na iya rage fiye da 22 kg a cikin makonni 40, amma yana sa a rasa ƙwayar jiki da ƙarfi. Gwajin bazuwar da ya kunshi mutane 120 ya nuna cewa, idan aka yi horon ƙarfi sau uku a mako, asarar kitse ta kasance iri ɗaya, amma an ceton kusan 1.1 kg na ƙwayar jiki mara mai kuma ƙarfi ya ƙaru.

Approach: 3, the human outcome, here as an animal-science moment. Palette: C, natural.

An old female lab mouse with slightly greying, ruffled fur sits upright on a researcher's open gloved palm, photographed at eye level in a close side-on view with a shallow depth of field. Behind it, a softly blurred animal facility window pours in real morning daylight, giving the scene a pale green-grey and warm-wood setting. The nitrile glove is a vivid electric green (#00e676), the single saturated accent. The mouse's whiskers and pink ears catch the light, and the researcher's white coat sleeve is just visible. Tones are natural: skin, soft cream bedding, sage walls. The mood is calm, careful and quietly hopeful, and it conveys age and care rather than drama. The image has no text, no labels and no readable writing.
longevity

Abin da ke cikin Ozempic ya tsawaita rayuwar berayen da suka tsufa – Ga dalilin

BY DR. SYNAPSE ·

Semaglutide, sinadarin da ke cikin Ozempic da Wegovy, ya tsawaita rayuwar berayen mata tsofaffi a wani sabon bincike da aka wallafa a *Nature* daga UC Berkeley. An ba su maganin ne a lokacin da suke da watanni 20, inda aka ga alamun rage tsufa da inganta aikin jiki. A gwajin beraye, semaglutide ya ba da sakamako mafi kyau fiye da rage kalori (CR) a kan sha’awar abinci, ƙwaƙwalwa da sarrafa sukari. Amma wannan bincike ya ƙunshi berayen mata ne kawai, ba ya nufin amfani ga mutane. Ga abin da sakamakon ke nuni da shi da abin da ba ya nuni ba.

**Approach: Conceptual metaphor. Palette: D, bold color field.**

A single clear glass of water sits on a saturated mustard-yellow backdrop, shot at a slight low three-quarter angle. A hand-held pen injector rests beside it, its body a matte white with a small electric green dial ring as the only green accent. Hard but clean studio light from the upper left throws a crisp, defined shadow across the yellow surface. Through the glass, the injector is refracted into two slightly offset images, suggesting a signal that is split and hard to read. The mood is calm, questioning and balanced, with no drama. The background is fully warm and bright, with no blue cast. The surface has a subtle paper-like texture. There is no text, no label and no face.
metabolism

Shin Ozempic da Mounjaro Suna Haifar da Tunani na Kashe Kai? Abin da Bincike 20 Ya Gano

BY DR. SYNAPSE ·

Shin magungunan Ozempic da Mounjaro na ƙara haɗarin damuwa, fargaba ko tunani na kashe kai? Bincike mai tsari da aka wallafa a *Rambam Maimonides Medical Journal* ya nuna cewa hujjojin da suka fi ƙarfi ba su tabbatar da wannan haɗari ba. Gwaje‑gwajen da aka yi da tsarin bazuwar ba su nuna ƙaruwa a haɗarin tunani na kashe kai, damuwa ko fargaba ga masu amfani da semaglutide ko tirzepatide ba. Sai dai akwai buƙatar ci gaba da sa ido ga waɗanda ke da tarihin cutar kwakwalwa.

This page is available in